CAR-T Cancer Drugs Front And Center At ARM Investor Day
Executive Summary
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
You may also be interested in...
Keeping Track: Oncology Filings Galore In Run-Up To ASCO Meeting
The latest cancer drug development news and highlights from our FDA Performance Tracker.
Too Sick For CAR-T? Kite Reports Cerebral Edema Death
Kite Pharma investors were spooked on May 8 when the company revealed that an extremely ill patient died from cerebral edema related to its lead CAR-T candidate – the same severe side effect that derailed Juno's competing cell therapy.
CAR T-Cells, Helping US Firms & An “Ambitious” Plan For Advanced Therapies In The EU
As companies like Novartis, bluebird bio and Kite Pharma press on with developing cancer treatments based on cutting edge CAR T-cell technology, the new chair of the European Medicines Agency’s Committee for Advanced Therapies, Martina Schüssler-Lenz, tells the Pink Sheet about plans to help makers of these and other innovative advanced therapies.